New York State Common Retirement Fund Sells 27,692 Shares of IQVIA Holdings Inc. (NYSE:IQV)

New York State Common Retirement Fund lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,355 shares of the medical research company’s stock after selling 27,692 shares during the period. New York State Common Retirement Fund owned approximately 0.08% of IQVIA worth $32,475,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Strategic Blueprint LLC boosted its holdings in IQVIA by 9.9% during the third quarter. Strategic Blueprint LLC now owns 2,965 shares of the medical research company’s stock worth $583,000 after buying an additional 266 shares during the last quarter. CX Institutional boosted its holdings in IQVIA by 20.0% during the third quarter. CX Institutional now owns 1,515 shares of the medical research company’s stock worth $298,000 after buying an additional 253 shares during the last quarter. Czech National Bank boosted its holdings in IQVIA by 45.7% during the third quarter. Czech National Bank now owns 32,005 shares of the medical research company’s stock worth $6,297,000 after buying an additional 10,040 shares during the last quarter. WS Portfolio Advisory LLC boosted its holdings in IQVIA by 49.0% during the third quarter. WS Portfolio Advisory LLC now owns 47,693 shares of the medical research company’s stock worth $9,384,000 after buying an additional 15,682 shares during the last quarter. Finally, GDS Wealth Management boosted its holdings in IQVIA by 7.3% during the third quarter. GDS Wealth Management now owns 36,351 shares of the medical research company’s stock worth $7,152,000 after buying an additional 2,461 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.

IQVIA Trading Down 2.8 %

Shares of IQVIA stock opened at $234.08 on Friday. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The stock has a market cap of $42.49 billion, a P/E ratio of 32.11, a P/E/G ratio of 2.33 and a beta of 1.50. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The business’s 50 day moving average is $245.35 and its 200-day moving average is $222.77.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the prior year, the business posted $2.54 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. Equities research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. Evercore ISI lifted their price objective on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Truist Financial lifted their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Barclays lifted their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. UBS Group lifted their price objective on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, BTIG Research assumed coverage on IQVIA in a report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.